ViroGates announces initiation of a clinical trial with HISS to clinically validate its commercial biomarker test for guiding early anakinra treatment of COVID-19 patients across 42 hospitals


suPARnostic® can become the first companion diagnostic device to aid in selecting and excluding COVID-19 patient groups for drug treatment. The product is already deployed for risk stratification and patient management of COVID-19 patients in European hospitals.

Läs hela meddelandet på ViroGates hemsida.

Läs mer..

Västra Hamnen Corporate Finance AB | Jungmansgatan 12 | 211 11 Malmö | 040-200 250 |